Table 1.

Demographic and clinic characteristics of patients

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Sex, age (years)	M, 71	F, 29	F, 51	F, 46	F, 64	M, 27	F, 20
Stage of melanoma BRAF status	IIIb V600E mutant	IIIc Wild type	IV V600E mutant	IV Wild type	IIc Wilde type	IIIc Wild type	IV V600E mutant
ICI regimen at the irAE-N onset	Nivolumab 3 mg/kg	Ipilimumab 1 mg/kg +nivolumab 3 mg/kg	Spartalizumab 400 mg/28 days	Ipilimumab 1 mg/kg +nivolumab 3 mg/kg	Nivolumab 3 mg/kg	Ipilimumab 3 mg/kg +nivolumab 1 mg/kg	Ipilimumab 3 mg/kg+nivolumab 1 mg/kg
Concomitant cancer treatment	0	0	Dabrafenib, Trametinib	0	0	0	0
No of ICI doses before irAE-N	1	1	4	2	1	2	1
Delay of neurological symptoms onset from ICI onset (days)	6	6	95	50	6	9	17

F, female; ICI, immune-checkpoint inhibitor; irAE-N, neurological immune-related adverse event; M, male.